Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A

References

• Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958–965
   PubMed Web of Science ®Google Scholar
• Heemskerk JWM, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186–193
   PubMed Web of Science ®Google Scholar
• Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in health volunteers. Thromb Res 1996; 81: 533–543
   PubMed Web of Science ®Google Scholar
• Vanschoonbeek K, Feijge MAH, van Kampen RJW, Kenis H, Hemker HC, Giesen PLA, Heemskerk JWM. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: Subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 478–484
   Web of Science ®Google Scholar
• Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: Monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589–591
   PubMed Web of Science ®Google Scholar
• Keularts IMLW, Hamulyak K, Hemker HC, Beguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand Type 1 and in mild haemophilia A patients. Thromb Haemost 2000; 84: 638–642
   PubMed Web of Science ®Google Scholar
• Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2: 623–628
   PubMed Web of Science ®Google Scholar
• Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L. Thrombin generation in severe haemophilia A and B: The endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90: 781–786
   PubMed Web of Science ®Google Scholar
• Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17–25
   PubMed Web of Science ®Google Scholar
• Association of Hemophilia Clinic Directors of Canada (AHCDC). AHCDC Clinical Practice Guidelines, Hemophilia and von Willebrand's disease: 2nd Management. 2nd, Update 2 from 7 July 1999
   Google Scholar
• Mannucci PM, Chediak J, Wahid H, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C, Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450–456
   Google Scholar
• Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9(Suppl 1)101–110
   PubMed Web of Science ®Google Scholar
• Zielosko A. Kontinuierliche Messung der zellgetriggerten Thrombinbildung. Entwicklung einer Methode zur Bestimmung der prokoagulatorischen Aktivität von Zellen. Dissertation zur Erlangung des Dr. rer nat. Fachbereich Pharmazie der Philipps-Universität Marburg. 2003; 69
   Google Scholar
• Hemker HC, Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134–138
   PubMed Web of Science ®Google Scholar
• Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551–558
   PubMed Web of Science ®Google Scholar
• Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity – assay discrepancies. Haemophilia 1998; 4: 641–648
   PubMed Web of Science ®Google Scholar
• Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Haematol 2001; 38: 13–23
   PubMed Web of Science ®Google Scholar
• Lee CA, Owens D, Bry G, Giangrande P, Collins P, Hay C, Gomperts E, Schroth P, Barrowcliffe T. Pharmacokinetics of recombinant factor VIII (Recombinate) using onse-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644–1647
   PubMed Web of Science ®Google Scholar
• Hubbard AR, Bevan SA, Lynne J. Potency estimation of recombinant factor VIII: Effect of assay method and standard. Br J Haematol 2001; 113: 533–536
   PubMed Web of Science ®Google Scholar
• Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Manucci PM. The ReFacto-AICE Study Group. J Thromb Haemost 2003; 11: 2283–2289
   Google Scholar
• Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: Phenotypic quantitation. J Thromb Haemost 2004; 2: 281–288
   PubMed Web of Science ®Google Scholar
• Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Hedner U, Roberts HR. The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagul Fibrinolysis 1998; 9(Suppl 1)S21–25
   PubMedGoogle Scholar
• Key NS, Nelsestuen GL. Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol 2004; 41: 51–54
   PubMed Web of Science ®Google Scholar
• Wegert W, Harder S, Bassus S, Kirchmaier CM. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa. Platelets 2005; 16: 45–50
   PubMed Web of Science ®Google Scholar
• Hemker HC, Béguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747–751
   PubMed Web of Science ®Google Scholar
• Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9: 348–352
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Haemophilia treatment protocols around the world: Towards a consensus. Haemophilia 1998; 4: 421
   PubMed Web of Science ®Google Scholar